Max Healthcare and Monash University sign MoU to advance research & academic collaboration

New Delhi: Max Healthcare, one of the largest private sector healthcare services companies in India, and Monash University, a global leader in medical research, have signed a Memorandum of Understanding (MoU) to establish a long-term partnership aimed at advancing medical research, training, and academic collaboration.

This strategic association brings together Max Healthcare’s extensive clinical expertise and Monash University’s world-class research capabilities to accelerate scientific breakthroughs, with the first flagship initiative centered on advancing research in triple-negative breast cancer (TNBC), one of the most aggressive and difficult-to-treat breast cancer subtypes.

The signing ceremony was attended by senior leaders from both institutions and marks the beginning of a robust framework for collaborative research across a wide spectrum of communicable and non-communicable diseases. The partnership spans everything from lab-based studies to real-world clinical research, along with joint education and training programmes designed to build capacity in key areas of modern healthcare.

Speaking on the partnership, Dr. Sandeep Budhiraja, Group Medical Director, Max Healthcare, said, “We are delighted to partner with Monash University, a world-class institution with a stellar reputation for biomedical research. This collaboration is a significant step towards our commitment to fostering innovation and research to deliver better care. By combining our clinical experience with Monash’s scientific capabilities, we are confident we can make a meaningful impact on the lives of patients in India and across the world, starting with our focused efforts on triple-negative breast cancer.”

Professor Roger Daly, Joint Head of Monash University’s Biomedicine Discovery Institute, highlighted the potential impact of the collaboration. “This new partnership provides an exciting opportunity to combine the respective strengths of Monash and Max Healthcare in discovery and clinical research to establish powerful pipelines for research translation to the clinic,” Professor Daly said. “Importantly, the first project will focus on triple negative breast cancer, an aggressive breast cancer subtype with limited targeted treatments, and we anticipate that this collaboration will lead to improved, precision treatment strategies,” he said.

The joint initiative under the MoU will span collaborative research projects, co-authored publications, staff and student exchange programmes, and specialised academic and training modules. Together, the two institutions aim to create a vibrant ecosystem where scientists and clinicians work side by side.